Depression severity in electroconvulsive therapy (ECT) versus pharmacotherapy trials.

Area of Science:

• Psychiatry
• Clinical Psychology
• Neuroscience

Background:

• Depression severity influences treatment selection.
• Electroconvulsive therapy (ECT) and pharmacotherapy are common depression treatments.
• Comparing baseline symptom severity in clinical trials is crucial for understanding treatment efficacy.

Purpose of the Study:

• To compare the severity of depressive symptoms in patients entering electroconvulsive therapy (ECT) clinical trials versus pharmacotherapy clinical trials.
• To evaluate differences in baseline Hamilton Rating Scale for Depression (HRSD) scores between ECT and pharmacotherapy trial participants.

Main Methods:

• Systematic literature search of MEDLINE/PubMed for ECT and pharmacotherapy trials in depression (1960-2011).
• Included 100 ECT studies and 7 pharmacotherapy trials using various Hamilton Rating Scale for Depression (HRSD) versions (HRSD15, HRSD17, HRSD21, HRSD24, HRSD28).
• Extracted baseline HRSD scores, sample size, and standard deviations for comparison.

Main Results:

• Patients in ECT trials had a mean baseline HRSD17 score of 27.6, significantly higher than the 21.94 in pharmacotherapy trials.
• A subanalysis of ECT studies using HRSD24 showed an even higher mean baseline score of 32.2.
• The observed differences in baseline severity were both statistically and clinically significant.

Conclusions:

• Patients entering ECT clinical trials exhibit greater depressive symptom severity compared to those in selected pharmacotherapy trials.
• These findings underscore the importance of ECT for managing severe and treatment-resistant depression.
• The data support the critical role of ECT in the therapeutic armamentarium for severe mood disorders.